| |
|
|
|
|
|
|
|||
|
BRIEF REPORT
From the Division of Transfusion Medicine, University
of Cambridge and National Blood Service East Anglia Centre, United
Kingdom; National Institute for Biological Standards and Control,
Potters Bar; Queen Elizabeth NHS Trust Hospital, King's Lynn, United
Kingdom; Central Laboratory of the Netherlands Red Cross Blood
Transfusion Service, Amsterdam, The Netherlands; and Thrombosis
Research Section, Department of Medicine, Baylor College of Medicine,
Houston, TX.
Autoimmune thrombocytopenia is generally caused by autoantibodies
against glycoprotein (GP) IIb-IIIa or GPIb-IX and occasionally against
GPIa-IIa or GPV. By investigating 38 rheumatoid arthritis (RA) patients
on gold therapy, 10 with profound thrombocytopenia and 28 nonthrombocytopenic controls, we showed that in all 10 patients with
thrombocytopenia, the platelet autoantibodies preferentially targeted
GPV but the presence of gold was not required for their reactivity.
Elevated levels of platelet-associated IgG (PAIgG) were observed in 8 of the 10 patients in whom the tests were performed. In 5 patients with
sufficient autologous platelets, the GPV specificity of PAIgG was
confirmed. Tests with GPV transfectants revealed that the antibodies
reacted with GPV independent of GPIb This article has been cited by other articles:
| |||||||||||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||